SCNI - BiondVax Pharmaceuticals Total Debt to Capital

The available price action vector on GURU.Markets shows that the total debt-to-equity ratio for Scinai Immunotherapeutics (SCNI) is 0.30. Scinai Immunotherapeutics develops inhaled biologics to combat viral infections. Patent protection shields the business from price wars, although success remains dependent on regulatory approval. The executive team aims to validate the platform's efficacy through strategic alliances with industry behemoths.

The total debt-to-equity ratio measures the proportion of borrowed funds within the financing structure, determining the business's level of dependence on external creditors and its overall financial stability. By analyzing the trend of the total debt-to-equity ratio, an investor assesses the ability of Scinai Immunotherapeutics (SCNI) to fund the development of the NanoAb platform and scale antibody production without a critical increase in debt load during the clinical trial period.